### IN THIS ISSUE

Highlighted research articles ........................................ 1195

---

### NEWS IN BRIEF

Important news stories affecting the community ............. 1200

---

### RESEARCH WATCH

Selected highlights of recent articles of exceptional significance from the cancer literature ............. 1205

---

### ONLINE

For more News and Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

---

### VIEWS

In The Spotlight

- **Shipping Out MEK Inhibitor Resistance with SHP2 Inhibitors** ........ 1210
  - P. Torres-Ayuso and J. Brognard
  - See article, p. 1237
- **Blood-Based Prediction of Tumor Relapse: The cfDNA Forecast** ....... 1213
  - G. Siravegna and R.B. Corcoran
  - See article, p. 1270
- **Different Originating Cells Underlie Intertumoral Heterogeneity in Lung Neuroendocrine Tumors** ........ 1216
  - K. Pozo, D.P. Kelenis, J.D. Minna, and J.E. Johnson
  - See article, p. 1316

---

### MINI REVIEW

Tumor Antigen Escape from CAR T-cell Therapy ............... 1219
  - R.G. Majzner and C.L. Mackall

---

### RESEARCH BREVES

**Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent-Front Mutations** ..................... 1227
  - **Précis:** The next-generation tyrosine kinase inhibitor repotrectinib has activity against wild-type and solvent-front mutant ROS1/TRK/ALK and achieved partial responses in two patients who progressed on prior TKI therapy.

---

**SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models** ........... 1237
  - **Précis:** The SHP2 inhibitor SHP099 increased the antitumor efficacy of MEK inhibition in pancreatic, lung, breast, and ovarian cancer models by preventing MEK inhibitor–induced reactivation of RAS–ERK signaling.
  - See commentary, p. 1210

---

**SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study** ........... 1250
  - **Précis:** In a phase Ib trial of 22 patients with advanced melanoma, intratumoral injection of the TLR9 agonist SD-101 in combination with PD-1 inhibition induced immune activation to produce antitumor responses.

---

**In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma** ........... 1258
  - **Précis:** In a phase I/II trial of 29 patients with indolent lymphoma, the TLR9 agonist SD-101 is well tolerated and reduced tumor burden at treated and untreated sites in combination with low-dose radiation.
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial ........................................ 1270
Précis: Combined mathematical modeling and serial analysis of ctDNA and tissues from patients with colorectal cancer treated with EGFR-targeted therapy predict individual patient relapse.

A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer ................................................................. 1286

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation ................................................. 1300
Précis: The reversible BTK inhibitor ARQ 531 has activity against ibrutinib resistance mutations and thus exhibits superior antitumor activity in mouse models of CLL and Richter transformation compared with ibrutinib.

Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin .............................................................. 1316
Précis: Small cell lung cancer can arise from different epithelial cell types, and the cell-of-origin defines the mechanisms underlying tumor evolution and metastatic progression.

Preclinical studies have suggested that TLR9 activation can enhance antitumor immunity, suggesting the potential for combination therapies using the TLR9 agonist SD-101. Ribas and colleagues assessed the safety and efficacy of SD-101 administered into peripheral metastatic lesions in combination with systemic anti–PD-1 therapy in 22 patients with advanced melanoma. The overall response rate was 78% among the 9 anti–PD-1 naïve patients and 15% among the 13 patients who had received prior anti–PD-1 therapy. Similarly, Frank and colleagues evaluated intratumoral SD-101 in combination with low-dose radiation in a phase I/II trial of 29 patients with untreated indolent lymphoma. Objective responses occurred in 28% of patients. Tumor reductions at nontreated sites occurred in 83% of patients. Collectively these trials indicate that SD-101 is safe and can be combined with anti–PD-1 therapy or low-dose radiation to produce systemic antitumor response in patients with melanoma or lymphoma, respectively. For details, please see the articles by Ribas and colleagues on page 1250 and Frank and colleagues on page 1258.
CANCER DISCOVERY

8 (10)

Cancer Discov 2018;8:OF6-1331.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://cancerdiscovery.aacrjournals.org/content/8/10">http://cancerdiscovery.aacrjournals.org/content/8/10</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>E-mail alerts</td>
<td>Sign up to receive free email-alerts related to this article or journal.</td>
</tr>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, use this link <a href="http://cancerdiscovery.aacrjournals.org/content/8/10">http://cancerdiscovery.aacrjournals.org/content/8/10</a>. Click on &quot;Request Permissions&quot; which will take you to the Copyright Clearance Center's (CCC) Rightslink site.</td>
</tr>
</tbody>
</table>